• Je něco špatně v tomto záznamu ?

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice

SJ. Snell Taylor, CM. Nielson, A. Breskin, B. Saul, Y. Yu, N. Alam, M. Eisen, J. Hippenmeyer, A. Janssens, T. Kozak, HA. Papadaki, D. Selleslag, JF. Viallard, C. Feistritzer, G. Kaiafa, M. Kelsh, K. Kilpatrick, MA. Brookhart, LJ. McGrath

. 2021 ; 38 (5) : 2673-2688. [pub] 20210418

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018648

INTRODUCTION: Romiplostim has been approved in Europe since 2009 to treat patients with chronic primary immune thrombocytopenia (ITP). Using real-world data from seven European countries, we measured the effectiveness and safety outcomes within 24 weeks following romiplostim initiation by duration of ITP: less than 3 months ("newly diagnosed"), 3-12 months ("persistent"), and more than 12 months ("chronic"). METHODS: Adults with ITP and ≥ 1 romiplostim administration between 2009 and 2012 were included. Endpoints included durable platelet response, median platelet count, rescue therapy, bleeding and adverse events. We used inverse probability of censoring weighted estimators to estimate cumulative risk of each outcome. There were 64 newly diagnosed, 50 persistent, and 226 chronic ITP patients at romiplostim initiation. RESULTS: Durable platelet response at 24 weeks ranged from 32% [confidence interval (CI): 18-46%] in newly diagnosed patients to 53% (CI 37-68%) in persistent patients. Median platelet count during follow-up ranged from 88 (CI 80-96) × 109/L in chronic patients to 131 (CI 102-160) × 109/L in newly diagnosed patients. CONCLUSION: Regardless of ITP duration, over half of patients discontinued concomitant ITP medications. Few adverse events were observed. Although only approved for chronic patients, estimates of the romiplostim treatment effect were similar across patients being managed in European clinical practice, regardless of ITP duration at romiplostim initiation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018648
003      
CZ-PrNML
005      
20210830100239.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-021-01727-5 $2 doi
035    __
$a (PubMed)33866516
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Snell Taylor, Sara J $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA. staylor@novisci.com
245    10
$a Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice / $c SJ. Snell Taylor, CM. Nielson, A. Breskin, B. Saul, Y. Yu, N. Alam, M. Eisen, J. Hippenmeyer, A. Janssens, T. Kozak, HA. Papadaki, D. Selleslag, JF. Viallard, C. Feistritzer, G. Kaiafa, M. Kelsh, K. Kilpatrick, MA. Brookhart, LJ. McGrath
520    9_
$a INTRODUCTION: Romiplostim has been approved in Europe since 2009 to treat patients with chronic primary immune thrombocytopenia (ITP). Using real-world data from seven European countries, we measured the effectiveness and safety outcomes within 24 weeks following romiplostim initiation by duration of ITP: less than 3 months ("newly diagnosed"), 3-12 months ("persistent"), and more than 12 months ("chronic"). METHODS: Adults with ITP and ≥ 1 romiplostim administration between 2009 and 2012 were included. Endpoints included durable platelet response, median platelet count, rescue therapy, bleeding and adverse events. We used inverse probability of censoring weighted estimators to estimate cumulative risk of each outcome. There were 64 newly diagnosed, 50 persistent, and 226 chronic ITP patients at romiplostim initiation. RESULTS: Durable platelet response at 24 weeks ranged from 32% [confidence interval (CI): 18-46%] in newly diagnosed patients to 53% (CI 37-68%) in persistent patients. Median platelet count during follow-up ranged from 88 (CI 80-96) × 109/L in chronic patients to 131 (CI 102-160) × 109/L in newly diagnosed patients. CONCLUSION: Regardless of ITP duration, over half of patients discontinued concomitant ITP medications. Few adverse events were observed. Although only approved for chronic patients, estimates of the romiplostim treatment effect were similar across patients being managed in European clinical practice, regardless of ITP duration at romiplostim initiation.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a idiopatická trombocytopenická purpura $x diagnóza $x farmakoterapie $7 D016553
650    _2
$a receptory Fc $x terapeutické užití $7 D011961
650    _2
$a rekombinantní fúzní proteiny $7 D011993
650    _2
$a thrombopoetin $x škodlivé účinky $7 D013926
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nielson, Carrie M $u Amgen Inc., Thousand Oaks, USA
700    1_
$a Breskin, Alexander $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA $u Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, USA
700    1_
$a Saul, Bradley $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA
700    1_
$a Yu, Ying $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA
700    1_
$a Alam, Naufil $u Amgen Ltd, Uxbridge, UK
700    1_
$a Eisen, Melissa $u Amgen Inc., Thousand Oaks, USA
700    1_
$a Hippenmeyer, Jane $u Amgen Inc., Rotkreuz, Switzerland
700    1_
$a Janssens, Ann $u University Hospitals Leuven, Leuven, Belgium
700    1_
$a Kozak, Tomas $u Charles University, Prague, Czech Republic
700    1_
$a Papadaki, Helen A $u University Hospital of Heraklion, Heraklion, Greece
700    1_
$a Selleslag, Dominik $u Algemeen Ziekenhuis Sint-Jan, Bruge, Belgium
700    1_
$a Viallard, Jean-Francois $u Hospital du Haut Leveque, Pessac, France
700    1_
$a Feistritzer, Clemens $u Universitätsklinik für Innere Medizin V Innsbruck, Innsbruck, Austria
700    1_
$a Kaiafa, Georgia $u AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
700    1_
$a Kelsh, Michael $u Amgen Inc., Thousand Oaks, USA
700    1_
$a Kilpatrick, Karynsa $u Amgen Inc., Thousand Oaks, USA
700    1_
$a Brookhart, M Alan $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA $u Department of Population Health Sciences, Duke University, Durham, UK
700    1_
$a McGrath, Leah J $u NoviSci, Inc., 201 W Main St, Ste 101, Durham, NC, 27701, USA
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 38, č. 5 (2021), s. 2673-2688
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33866516 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100239 $b ABA008
999    __
$a ok $b bmc $g 1689674 $s 1139094
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 38 $c 5 $d 2673-2688 $e 20210418 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace